09:23 AM EST - BioVaxys Technology Corp : Announces studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.07.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=7386460572424080
